1 comparing cyclophosphamide and VP16 containing conditioning regimens for children with acute lymphoblastic leukaemia (ALL). I was surprised that the authors did not cite the recent very large Centre for International Blood and Marrow Transplant Research (CIBMTR) study on precisely the same topic. 2 This study was of over 500 patients including 264 children (o20 years), much larger than the number of patients reported in their study. Although ALL clearly behaves differently in children, the findings of the CIBMTR study did not vary with age and, consequently, this letter reports the results in all patient age groups. It is of some relevance to compare and contrast the findings in the two studies. In accordance with the way the results are reported in the BMT paper, Table 1 shows the comparative transplant related mortality (TRM) and relapse rates in all (CR1 and CR2 patients) and the event-free survival and overall survival (OS) in CR2 patients; the two studies are thereby directly compared.
There are important differences to consider. All patients in the Toronto study received 12 Gy of total body irradiation (TBI) in six fractions; there was no opportunity to examine the effect of TBI dose within this study. The CIBMTR study divided patients into groups depending on their TBI dose (o13 Gy and 413 Gy). Over half the patients in the CIBMTR study were in CR1 compared with only a quarter in the Toronto study.
The CIBMTR study found that the dose of TBI was of great importance. In particular, in CR2 patients the regimen of cyclophosphamide and o13 Gy of TBI (the dose in the Toronto study) resulted in inferior OS to cyclophosphamide and 413 Gy TBI (not shown) or VP16 and TBI (Table 1 ), and the study was able to conclude that this regimen (perhaps the worldwide standard regimen) should not be used. There were similar effects in CR1 patients but they did not achieve statistical significance. Cyclophosphamide and o13 Gy of TBI was also associated with a trend towards a higher incidence of relapse on multivariate analysis compared with VP containing regimens. This is in agreement with the Toronto study where the incidences of relapse were 65 and 41% in the cyclo/TBI and VP/TBI groups, respectively (P ¼ 0.2 in 59 matched related allograft patients). In both studies, the two regimens did not differ significantly in their effect on TRM.
To summarise, the relatively small Toronto study found that the two regimens produced similar survival in children with ALL but the larger CIBMTR study found that VP/TBI produced superior survival, particularly in CR2 patients. 2 However, our study was submitted before their publication and therefore their larger study was not cited in our reference list. We appreciate the comments from Dr Marks highlighting some subtle issues regarding this very important subject. In the CIBMTR study that looked only at sibling allografting, there was an advantage for recipients of higher dose of TBI (X13 Gy) or recipients of VP16 compared to cyclophosphamide in advanced disease. In agreement with the CIBMTR results, in our study there was a trend towards more relapse for children conditioned with cyclophosphamide receiving matched sibling allografts compared to VP16 (65 vs 41%, P ¼ 0.2) with a comparable probability of acute and chronic graftversus-host disease (GVHD), Tables 2 and 3. 1 Nonetheless, for unrelated allografts recipients, the effect was the opposite with less relapse and more probability for acute and chronic GVHD in the cyclophosphamide group compared to the VP16 group resulting in better 3-year event-free survival for the cyclophosphamide group compared to the VP16 group (64 vs 49%), Tables 2 and 3 . 1 It is difficult to extract conclusions from nonsignificant values. However, these trends may suggest that there are subtle differences between the two most commonly used conditioning regimens for ALL and perhaps we should consider studying the effect of different conditioning regimens depending on disease stage and donor source, and not to use a uniform regimen for all patients. VP16 is well known for its antileukemic effect, and when utilizing sibling donors there is less GVHD/graft-versus-leukemia (GVL) effect, therefore, VP16 may be of choice in this scenario particularly in advanced disease. On the other hand, cyclophosphamide is well known for its immunosuppressant effect and may be of choice when utilizing unrelated donors to enhance engraftment and maximize GVHD/GVL effect from the unrelated graft. We agree that the CIBMTR study is larger and there was an opportunity to examine the effect of different TBI doses on outcome both in children and adults but our smaller pediatric only study has its' own merits. In particular, it is a single institution study where there is uniform stem cell and radiation technology, donor selection including human leukocyte antigen typing, GVHD prophylaxis and treatment and supportive care compared to the CIBMTR study where eligible cases came from 111 reporting teams with a trend towards center effect (P ¼ 0.07) and almost all recipients of VP16 and TBI (X13 Gy) came from one center. In addition, with this more intensive conditioning regimen, transplant-related mortality was the least in that particular center. Finally, we agree that to address the issue of which is the best conditioning regimen for pediatric and adult ALL, a randomized trial is warranted as suggested at the end of the CIBMTR study. We have to acknowledge, that both VP16 and cyclophosphamide along with TBI were used for the last 20 years as conditioning regimens for ALL with somewhat stable outcome and both have not improved survival significantly over the years. It is probably worthwhile investigating new novel agents in the conditioning regimens especially for those with advanced disease.
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